ASND Company Profile and Key Details

Ascendis Pharma A/S generated EPS of -$4.20 over the past year. Five-year average earnings growth is 14.76%. The latest quarter delivered EPS of -$1.36. The next quarter is forecast at $0.46. Next year's EPS is expected at $18.33. Analyst sentiment is bullish. Analyst rating data shows there are 20 Strong Buy ratings, 10 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $342.00 to $203.00. The high target offers 36.89% upside. The low target suggests -18.75% downside. The mean target is $264.77. This offers 5.98% upside. Ascendis Pharma A/S earnings surprise history is a mixed track record. The quarter that ended November 12, 2025, missed forecasts by 231.36%. The prior quarter beat by -34.51%. Over the last six quarters, Apple has recorded several small beats. These include 33.12% in September 03, 2024.

Ascendis Pharma A/S has 61.39 million shares outstanding. The public float is 60.88 million shares, elevated short interest at 7.56% of float. This equals 3.87 million shares. The short ratio is 5.26 days. Institutional investors hold 106.97% of the float. Insiders own 0.76%.

Our AI price prediction model suggests that Ascendis Pharma A/S stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 4.05%, with price expected at $259.97 by April 28, 2026, within a range of $252.68 to $267.49 3-Month Outlook: Projected rise of 12.84%, reaching $281.91 by July 13, 2026, with a range of $278.84 to $285.31. 1-Year Outlook: Projected gain of 18.85%, with price at $296.93 by April 14, 2027, within a range of $291.33 to $304.51.

Ascendis Pharma A/S (NASDAQ:ASND) shares are flat 1.1% year-to-date currently trading near 52-week highs band. Short-term momentum has been positive over the last quarter, despite recent volatility. Valuation shows Ascendis Pharma A/S trading at a premium to the broader market with a P/E of -56.77. Analyst sentiment is bullish, with the majority of ratings in Outperform territory and a mean price target of $191.92, suggesting -23.18% downside. Our AI forecast model points to short-term strength (4.05% over two weeks), a medium-term rise (12.84% over three months), and a longer-term gain (18.85% over one year), with expected trading ranges indicating moderate volatility.